ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Physician Bonus Denied Some Agencies; NIH Status Unsure

January 18, 1991

DCE Advisors OK RFAs In Occupational Cancer, H. Pylori

April 1, 1994

Black Women More Likely To Delay Diagnosis, Treatment

July 29, 2005

Triple-Negative Breast Cancer Equally Aggressive in Whites

February 25, 2011

DCT Advisors OK 4 Contract Concepts In Therapeutics

June 28, 1991

NCI To Recompete NSABP in 1995, Chabner tells Senate

May 20, 1994